HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib, last Monday, Revolution Medicines is not resting on its laurels. The Bay Area biotech spent several recent days in San Diego highlighting earlier data for its lead candidate and the rest of its pipeline.

By FierceBiotech · Apr 22, 2026 · via FierceBiotech
AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
pipelineformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
PipelineFiercePharma ↗
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain…
May 25, 2026
ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
PipelineFiercePharma ↗
ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with…
May 24, 2026
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
PipelineFiercePharma ↗
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and …
May 23, 2026